Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage

Background: The overexpression of the human epidermal growth factor receptor-2 (HER2) gene is present in 20~25% of breast cancer (BC) patients, contributing to an inferior prognosis. Recent clinical trials showed that pyrotinib has promising antitumor activities and acceptable tolerability for those...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Yuwen, Zhang, Zhuolin, He, Xuan, Cai, Lele, Wang, Xiao, Li, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497482/
https://www.ncbi.nlm.nih.gov/pubmed/36135045
http://dx.doi.org/10.3390/curroncol29090476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497482/
https://www.ncbi.nlm.nih.gov/pubmed/36135045
http://dx.doi.org/10.3390/curroncol29090476

Ejemplares similares